IGF1 and Parkinson disease: However, several clinical correlations in PD patients have reported an augmentation in IGF-1 levels at the onset of the disease, which suggests, given the preclinical results, an ongoing compensatory or “fight-to-injury” mechanism, since as the disease progresses such elevation dissipates.